Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier.
about
Organelle targeting: third level of drug targetingMolecular simulations of carbohydrates and protein-carbohydrate interactions: motivation, issues and prospectsDeletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease miceBiosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient miceDisruption of adaptive energy metabolism and elevated ribosomal p-S6K1 levels contribute to INCL pathogenesis: partial rescue by resveratrolGene therapy for the nervous system: challenges and new strategies.Evaluation of neurodegeneration in a mouse model of infantile batten disease by magnetic resonance imaging and magnetic resonance spectroscopy.Nanoparticle transport across the blood brain barrier.Endocytic mechanisms for targeted drug deliveryStructural glycobiology: a game of snakes and ladders.Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II.Neural stem cell transplantation as a therapeutic approach for treating lysosomal storage diseases.An overview of nanosomes delivery mechanisms: trafficking, orders, barriers and cellular effects.Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice.Adeno-associated virus vector-mediated transduction in the cat brain.
P2860
Q27014902-E962BE16-CE8D-46DD-B52F-951DD50B33ABQ27686945-B20E245E-3665-49CE-B385-D4D464F1A827Q28507753-D80BC404-14CE-44DE-93A2-0E4DDB5C51B9Q28513876-91B1A749-BA28-4469-BF38-2C3D2D22D5EBQ34597859-C07B090B-605C-49FD-8879-A7BC6B9003C7Q35340196-BCBD13F8-D04E-472F-8631-4B5DD6F3471CQ36013977-AC20EF5B-012D-4BEF-8438-83D9F3F7D8BEQ36812347-47AFABDE-A6C7-44F8-B04B-F60045FFE336Q36894849-4A9808AF-38FF-4B8F-8B06-77BE78D74986Q37129248-EACD7CD5-6BFD-4308-BF32-107B0E742E12Q37259816-87693C17-ED8E-4BEC-9A23-CD7F5D429C59Q37929618-8A700B3E-549E-4CDF-B070-B417DAD47118Q38557213-91273B41-D507-4CC6-9B55-F465047FA616Q41838643-38489E61-5231-425C-8FCE-A589CF7F7365Q45711198-A945F05A-FB64-451C-9F7A-73673D46E01E
P2860
Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Brain-directed gene therapy fo ...... yond the blood- brain barrier.
@ast
Brain-directed gene therapy fo ...... yond the blood- brain barrier.
@en
Brain-directed gene therapy fo ...... yond the blood- brain barrier.
@nl
type
label
Brain-directed gene therapy fo ...... yond the blood- brain barrier.
@ast
Brain-directed gene therapy fo ...... yond the blood- brain barrier.
@en
Brain-directed gene therapy fo ...... yond the blood- brain barrier.
@nl
prefLabel
Brain-directed gene therapy fo ...... yond the blood- brain barrier.
@ast
Brain-directed gene therapy fo ...... yond the blood- brain barrier.
@en
Brain-directed gene therapy fo ...... yond the blood- brain barrier.
@nl
P2860
P356
P1476
Brain-directed gene therapy fo ...... yond the blood- brain barrier.
@en
P2093
Carole Vogler
William S Sly
P2860
P304
P356
10.1073/PNAS.102175599
P407
P577
2002-04-01T00:00:00Z